drugset / Trial / NCT05097248
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
Phase 2
Unknown
52 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · collabJiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, single-arm, multi-center, prospective clinical study of camrelizumab in combination with liposomal doxorubicin and losartan in patients with advanced or locally advanced triple-negative breast cancer who had received no more than 1 prior line of chemotherapy. Our aim was to explore the efficacy and safety of it.
Timeline
- Start
- 2021-10
- Primary completion
- 2024-10
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Subject | Losartan | Other / unclassified | 100 mg | Oral |